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Abstract 
 Schizophrenia is a debilitating disease that affects approximately 21 million people 
worldwide (APA, 2013). The gold standard of treatment of schizophrenia is antipsychotic 
medications. Unfortunately, approximately 50% of patients become non-compliant with their 
prescribed medications (Sadock, Sadock & Ruiz, 2015). The purpose of this DNP project was to 
determine the effect of implementing an education intervention regarding long acting injectable 
(LAI) antipsychotics on the knowledge of advanced practice providers working at a state 
psychiatric hospital. The advanced practice providers that participated in this DNP project 
completed a pre-education assessment, attended a brief educational session regarding LAI 
antipsychotics, and completed a post-education assessment two weeks later.  Though the results 
were limited by the number of participants, it was found that after implementing an educational 
session regarding LAI antipsychotics advanced practice providers had improved knowledge 
about and self-efficacy in prescribing of LAI antipsychotics, and reported a greater willingness to 
prescribe LAI antipsychotics in the future.
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Background and Significance 
Problem Identification 
Schizophrenia is a debilitating disease characterized by cognitive, behavioral and 
emotional dysfunctions that cause significant impaired occupational or social functioning. It 
typically presents with delusions, hallucinations and disorganized speech (APA, 2013). The 
overall lifetime prevalence of schizophrenia is approximately 0.7% among populations 
worldwide (APA, 2013) and more than 23 million people worldwide are affected by this disease 
(WHO, 2019). Schizophrenia is more common and typically presents earlier among males, but 
both males and females are affected by this chronic disease (WHO, 2019).   
Context of the Problem 
There is a two to three percent greater than expected early mortality rate among those 
with schizophrenia than the general population (WHO, 2019). Having a mental illness like 
schizophrenia is a barrier to appropriate medical care and is associated with medical morbidity 
and mortality (Gur et al., 2018). This is largely attributed to comorbid medical problems such as 
cardiovascular disease, metabolic disease and infections (WHO, 2018). Unfortunately, suicide is 
also a large contributing factor to mortality among those diagnosed with schizophrenia; nealy 
20% of this population attempt and about 5%-6% die as a result of suicide (APA, 2013). 
Medication nonadherence is also associated with a greater risk for suicide and medical morbidity 
and mortality among people with schizophrenia (El-Mallakh & Findlay, 2015). Despite first-line 
antipsychotic medications being effective in approximately 70%-80% of this population, an 
estimated that 50% become nonadherent to their medication regimen (El-Mallakh & Findlay, 
2015).  
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Scope and Consequences of the Problem 
Antipsychotic medications are the gold standard for schizophrenia treatment and consist 
of older first-generation antipsychotics and newer second-generation antipsychotics (Sadock, 
Sadock & Ruiz, 2015). Unfortunately, oral antipsychotic medication nonadherence is a frequent 
problem and is the most common cause of a psychotic relapse (Kaplan, Casoy & Zummo, 2013). 
The Clinical Antipsychotic Trials of Intervention Effectiveness study report that 74% of those 
diagnosed with schizophrenia become nonadherent with their antipsychotic medication within 18 
months of the medication being prescribed (Higashi et al., 2013). Approximately 53% to 72% 
percent of those who are nonadherent with antipsychotic medications experience a psychotic 
relapse (Sadock, Sadock & Ruiz, 2015). However, Long Acting Injectable (LAI) antipsychotics 
are an alternative to traditional oral and older depot antipsychotics (Kaplan, Casoy & Zummo, 
2013).  LAIs are also associated with improved medication compliance and improved patient 
outcomes (Kaplan, Casoy & Zummo, 2013).  
Evidenced Based Intervention 
Provider education has been demonstrated to be an effective evidence-based intervention 
in improving knowledge about schizophrenia and its treatment (Turrina et al., 2008). LAI 
antipsychotics have been shown to increase the success of schizophrenia treatment by improving 
medication adherence, maintaining more consistent medication bioavailability, lowering 
symptom relapse rates, and improving patient outcomes (Brissos, Veguilla, Taylor, Balanza-
Martinez, 2014). In comparison to oral antipsychotics, LAIs have also been associated with 
decreased number of ER visits, decreased lengths of hospital stays, and decreased rates of re-
hospitalization among those with schizophrenia (Lafeuille et al., 2013).  Provider education on 
LAI antipsychotics can also be a relatively inexpensive intervention to improve the care of those 
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diagnosed with schizophrenia. The average cost per learner in continuing medical education is as 
low as $37 (Sullivan, 2018).  
When searching for educational opportunities regarding LAI antipsychotics a variety of 
published research papers and recommendations from health networks can be found, but no 
educational programs regarding LAI antipsychotics are currently available. The 
Psychopharmacology Institute (2018) has a published guide entitled “Long-Acting Injectable 
Antipsychotics: A Summary for Prescribers” which summarizes the most clinically relevant 
information regarding the use of LAI antipsychotics (Guzman, 2018). This guide is a four-page 
document written by Dr. Flavio Guzman, who is a psychiatrist and assistant professor of 
pharmacology at the University of Mendoza (Psychopharmacology Institute, 2018). This 
resource was intended to be used as a guide to reference the most clinically relevant features and 
prescribing facts of LAI antipsychotics (Guzman, 2018). For this DNP project the guide is used 
as the content for an educational session delivered to advanced practice providers. It was further 
chosen because it clearly presents who should receive LAI antipsychotics, the practical 
considerations of prescribing LAI antipsychotics, and the potential advantages and disadvantages 
of LAI antipsychotics (Guzman, 2018).  
Purpose of the Project 
The purpose of this project was to determine the effect of implementing an education 
intervention regarding LAI antipsychotics on the knowledge of advanced practice providers. The 
project aims were to identify barriers to prescribing LAI antipsychotics among advanced practice 
providers; assess the effect of implementing education regarding LAI antipsychotics on 
providers comfort in prescribing LAI antipsychotics; and examine the effect of implementing 
education regarding LAI antipsychotics on providers likelihood to prescribe LAI antipsychotics.   
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Theoretical Model 
The theoretical model that guided this DNP project was the Diffusion of Innovation 
Theory, which focuses on the dissemination of new information (Zhang, Yu, Yan, & Spil, 2015). 
The Diffusion of Innovation Theory categorizes an innovation into one of five possible qualities 
including the relative advantage, compatibility, complexity, trialability and observability of the 
innovation. If the innovation is perceived by others as beneficial, it will likely be adopted 
(Zhang, Yu, Yan, & Spil, 2015). This theory also states that the spread of innovation is a process 
by which people adopt new ideas, practices, and philosophies. When a new idea is developed, a 
limited number of people are initially open to the idea. With time, however, the new idea spreads 
to more people and may become accepted by most. The theory categorizes people into one of 
five categories (innovators, early adopters, early majority, late majority, and laggards) based on 
the state in which a person adopts an innovation (Kaminski, 2011).  
When implementing an educational session on LAI antipsychotics, it was important to 
present the information of LAI antipsychotics as beneficial. It was also important to understand 
the characteristics of the advanced practice providers who would participate in the educational 
session. Based on the Diffusion of Innovation Theory, most advanced practice providers fall into 
the early majority category because they want proven applications that have reliable results. This 
includes utilizing prescribing practices that come with appropriate references. Considering these 
characteristics, it was likely that the advanced practice providers would perceive LAI 
antipsychotic education as a beneficial endeavor.  
Review of Literature 
 LAI antipsychotics are an effective alternative approach to oral antipsychotics and can 
improve medication adherence to antipsychotic medication (Kaplan, Casoy & Zummo, 2013). 
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Greene et al. (2018) reported that medication adherence and discontinuation were examined 
between two separate groups of patients that received LAI antipsychotics versus oral 
antipsychotics. Those who received LAI antipsychotics were more adherent and 20% less likely 
to discontinue their antipsychotic medication (Green et al., 2018). Adherence to antipsychotic 
medications is important because it is the leading preventative measure of symptom relapse 
among those with schizophrenia (Kaplan, Casoy & Zummon, 2013). LAI antipsychotics have 
shown to prevent symptom relapse. A systematic review by Zhornitsky and Strip (2012) 
indicated that psychotic relapse is lower with LAI antipsychotics versus oral antipsychotics. 
Further evidence-based support for the use of LAI antipsychotics can be found in The Electronic 
Schizophrenia Treatment Adherence Registry, an international long-term study of schizophrenia 
patients that are started on new treatment. A study from the registry data showed that after 12 
months of switching from an oral to an LAI antipsychotic the percentage of patients that relapsed 
was considerably lower for those who received LAI antipsychotics versus those who took oral 
antipsychotics (14.6% vs 52.2%) (Olivares, Rodriquez-Martinez, Buron, Alonso-Escolano, 
Rodriguez, 2008). Rates of hospitalization and lengths of stay are also noted to be lower among 
those treated with LAI versus oral antipsychotics (Lafeuille et al., 2013). A systematic review by 
Park et al. (2018) found strong evidence that LAI antipsychotics have higher efficacy at treating 
schizophrenia. In the review, those treated with LAI antipsychotics had lower rates of relapse 
and shorter hospital stays as compared to those on oral antipsychotics (Park et al., 2018). Peng et 
al. (2011) found that after starting LAI antipsychotics, hospital rates among those with 
schizophrenia declined from 49.7% to 22.4 % and lengths of hospital stay declined from 7.3 to 
4.7 days.   
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Educational outreach visits can be effective in improving knowledge and changing 
practice among health care providers (O’brien et al., 2007). Educational outreach visits are face-
to-face educational sessions in which trained individuals visit healthcare providers where they 
practice and provide education about their practice (O’Brien et al., 2007). This type of visit can 
be more effective than no educational intervention or other types of education such as 
distribution of educational materials (Grimshaw, 2004). Prescribing practices have specifically 
been influenced by educational outreach visits in several research studies (Freemantle et al., 
2003; Fretheim et al., 2006; Soumerai, Salem-Schatz, & Avorn, 1999; Witt, Knudsen, Ditlevsen, 
& Hollnagel, 2004). For example, a randomized control trial which evaluated the effectiveness of 
educational outreach visits on prescribing practices among 162 healthcare providers in 69 
practices found that smaller practices had substantial reactions to educational outreach visits 
(Freemante et al., 2003). Smaller practices improved in prescribing according to practice 
guidelines by 13.5%, versus larger practices that only improved by 1.4% (Freemante et al., 
2003).  Freemante et al. (2003) also found that no specific guideline proved more or less 
effective than other guidelines, rather, small practice size was most consistent with improved 
prescribing patterns.  
A thorough review of the literature did not result in research pertaining to specific 
education of providers specifically about LAI antipsychotics. However, a review of the literature 
supports the notion that education sessions cane improve provider knowledge regarding 
medications and prescribing practices on a variety of medications (Freemante et al., 2003, 
Avourn & Soumerai, 1983, Diwan et al., 1995). 
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Agency Description  
Setting 
The DNP project was implemented at Eastern State Hospital (ESH) in Lexington, 
Kentucky. ESH is a state psychiatric hospital in Lexington, KY, that provides care to residents 
from the rural 50 counties of the eastern region of Kentucky. Up to 196 patients can be receive 
care at a given time by approximately 15 providers, which consists of psychiatrists, nurse 
practitioners and physician assistants (ESH, n.d.). 
Target Population 
Advanced practice providers, which included psychiatric mental health nurse 
practitioners and physician assistants, were the target population for this project. The inclusion 
criteria were board certified advanced practice providers (Psychiatric Mental Health Nurse 
Practitioners or Physician Assistants) who provided care to patients on an inpatient care unit at 
ESH. Exclusion criteria were advanced practice providers that worked solely in the admissions 
unit because LAI antipsychotics are not regularly prescribed by providers in the admissions unit. 
It was anticipated that the sample size would consist of 10 advanced practice providers; however, 
only four advanced practice providers participated in the educational intervention. The sample 
consisted of two psychiatric mental health nurse practitioners and two physician assistants.  
Congruence of DNP Project and ESH 
 The mission of ESH is to instill hope, inspire recovery and improve the overall wellbeing 
of Kentuckians through providing excellent mental healthcare (ESH, n.d.). This mission is 
achieved through their values that include diversity, innovation, respect, compassion and 
teamwork (ESH, n.d.). The purpose of this DNP project was to improve the knowledge of 
advanced practice providers by implementing an educational session regarding LAI 
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antipsychotics. This project contributed to ESH’s mission by improving advanced practice 
providers knowledge of long acting injectable antipsychotics which will likely improve the 
wellbeing of many Kentuckians with mental illness.  
Description of Stakeholders 
 The stakeholders of this project included the advanced practice providers, the chief 
medical officer and the chief nursing officer at ESH. Improvement in advanced practice provider 
knowledge regarding long acting injectable antipsychotics is likely most important to the key 
stakeholders, which are those diagnosed with schizophrenia.  
Site-Specific Facilitators and Barriers 
 There were several people that facilitated the implementation of this project at ESH. Both 
the chief nursing officer and chief medical officer supported and approved this project. The chief 
medical officer was helpful in communicating between the primary investigator and the 
advanced practice providers, and allowed for the advanced practice providers to have time to 
complete the project during their regularly scheduled working hours. The assistant to the chief 
medical officer was also helpful in scheduling a designated room for the primary investigator to 
meet with the advanced practice providers. The only identified barrier was that some advanced 
practice providers were not able to participate in the project due to competing work obligations, 
such as patient needs, during the time of the educational sessions. 
Project Design 
A pre and posttest design was used to examine advanced practice provider’s knowledge 
and level of comfort prescribing long acting injectable antipsychotics. An existing assessment 
tool to assess provider knowledge regarding LAI antipsychotics was unable to be found in the 
literature, so a pre and post education assessment tool was developed by the primary investigator. 
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Face validity of the assessment tools were established by having expert psychiatric mental health 
nurse practitioners review and recommend edits to the assessment tools. The pre-education 
assessment tool (shown in Appendix A) examined the advanced practice providers’ knowledge 
regarding the advantages, frequency of side effects and appropriate prescribing of LAI 
antipsychotics. It also assessed for qualitative data asking the advanced practice providers what 
they perceived as the largest barriers to prescribing LAI antipsychotics and if they were 
comfortable prescribing LAI antipsychotics. The post-education assessment tool (shown in 
Appendix B) again assessed the advanced practice providers’ knowledge regarding the 
advantages, frequency of side effects and appropriate prescribing of LAI antipsychotics. The 
post-education assessment tool also asked if the advanced practice providers felt more 
comfortable prescribing LAI antipsychotics and if they thought they would prescribe LAI 
antipsychotics more often after receiving education about LAI antipsychotics. No demographic 
data on the advanced practice providers was collected because collecting such data with a small 
sample size would reduce anonymity.   
Project Methods 
Procedure 
An expedited medical IRB application was submitted to and approved by the University 
of Kentucky Institutional Review Board. Advanced practice providers who were providing who 
met eligibility criteria at ESH were invited via email on January 18, 2019, to take part in the 
project. A message from the primary investigator was emailed by the ESH medical director, via 
departmental email, inviting the advanced practice providers to participate in the study. This 
message was the initial contact of the primary investigator with the advanced practice providers 
regarding this project. The email message described the study, requested the advanced practice 
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providers participation in the study, and included an informed consent form. The advanced 
practice providers that volunteered to be in the study met with the primary investigator at ESH to 
complete the informed consent, to complete a 20-minute pre-education written assessment, and 
to attend a brief educational session on January 24, 2019. The advanced practice providers were 
then given a paper copy of the educational material by the Psychopharmacology Institute to 
review during their own time. The primary investigator met with the advanced practice providers 
at ESH two weeks later, on February 7, 2019, for a post education 20-minute written assessment.   
Results 
 Pre and post education assessment results were compared to determine if there was a 
response to the educational intervention. No inferential analyses were completed because the 
small sample size. The pre-education assessment results showed that 75% of the participants 
were quite knowledgeable about most aspects of LAI antipsychotics. Every participant correctly 
answered the questions regarding LAI antipsychotics effects on risk of rehospitalization and the 
potential advantages of LAI antipsychotics. Results from the pre-education assessment also 
showed that every participant correctly answered which LAI antipsychotic requires a two-week 
bridge therapy with an oral antipsychotic. However, 75 % of the participants incorrectly 
responded to what should be done with an oral antipsychotic after the patient has a therapeutic 
level of a LAI antipsychotic. One participant answered 100% of the eight knowledge-based 
questions correctly, one participant answered 87.5% of the eight knowledge-based questions 
correctly, and one participant answered 75% of the eight knowledge-based questions correctly. 
Though most of the participants answered a majority of the questions correctly, one of the 
participants answered 50% of the knowledge-based questions incorrectly.  
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 Post-education assessment results revealed improved knowledge regarding LAI 
antipsychotics among the participants. Knowledge among the participants regarding what to do 
with an oral antipsychotic after a patient has a therapeutic level of a LAI antipsychotic improved 
from the pre-education assessment to the post education assessment (25% to 75%). Knowledge 
regarding who should receive LAI antipsychotics, side effects, and plasma concentrations all 
improved to 100% of the participants answering those questions correctly. However, the 
percentage of participants that correctly answered which LAI antipsychotic require a two-week 
bridge therapy dropped from 100% to 75%. The same participant that correctly answered 100% 
of the pre-education assessment questions, again answered 100% of the post education questions 
correctly. The participant that answered 87.5% of the pre-education assessment questions 
correctly again correctly answered 87.5% of the post education assessment questions. The 
participant that answered 75% of the pre-education assessment questions correctly answered 
100% of the post-education assessment questions correctly. The participant that answered 50% 
of the pre-education assessment questions correctly answered 87.5% of the post-education 
assessment questions correctly.  The percentages of correct response among the group of 
participants is shown in Table 1.  
 The pre-education assessment also asked the participants what they perceived to be the 
largest barriers to prescribing LAI antipsychotics. A common theme was mentioned by three of 
the participants. They wrote that the difficulty associated with finding a place for patients to 
receiving LAI antipsychotic injections after being discharged from the hospital was a 
considerable barrier to prescribing LAI antipsychotics. One of the participants also mentioned 
that cost was a barrier.  Both the pre and post education assessments asked the participants to rate 
their comfort level of prescribing LAI antipsychotics on a Likert scale. Three of the four 
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participants strongly agreed that they were comfortable prescribing LAIs prior to the education 
session. All of the participants strongly agreed after the education session. Each of the 
participants also strongly agreed that after the educations sessions they would prescribe LAI 
antipsychotics more often. 
Discussion 
 The findings of this DNP project support the notion that implementing an educational 
session regarding LAI antipsychotics can improve the knowledge of advanced practice providers. 
The results also showed that educational sessions can improve advanced practice providers 
comfort level in prescribing LAI antipsychotics. Improving advanced practice providers 
knowledge and comfort levels of prescribing LAI antipsychotics may explain why the advanced 
practice providers believed they would prescribe LAI antipsychotics more often. 
 The results of this DNP project were similar to the results of prior research that 
implementing provider education can improve provider knowledge and comfort level (Dacey et 
al., 2012; Drexel et al, 2011); this is the first time that there has been an analysis to determine the 
effect of implementing an education intervention specific to APPs regarding LAI antipsychotics. 
This is important because of the number of APPs that are providing care to patients is rapidly 
growing (Auerbach, Staiger & Buerhaus, 2018). This is also important because of the impact that 
LAI antipsychotics can have in the treatment of those with schizophrenia.  
 The Psychopharmacology Institutes “Long-Acting Injectable Antipsychotics: A 
Summary for Prescribers” (Guzman, 2018) guide was of value to use for this project because it 
contains information that is of value to APPs. It contains the most relevant information of LAI 
antipsychotics including information regarding who should receive LAI antipsychotics, key 
prescribing facts, and the potential advantages and disadvantages of LAI antipsychotics. It is 
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unknown if the guide has been used as the content of an educational session in prior studies, but 
the guides succinct format allowed for the educational session of this DNP project to be brief and 
focused on the information that is most applicable to APPs practice. Though the guide is 
valuable, it only gives the typical dosing of the older first-generation LAI antipsychotics, and 
does not include their practical considerations.  
 APPs working in the hospital setting are fortunate to work with staff, such as registered 
nurses, who can administer LAI antipsychotics. In the community setting, however, 
administering LAI antipsychotics can be difficult due to the lack of needed staff to ensure 
injections are given. The APPs in this DNP project perceived that the difficulty associated with 
continuing LAI antipsychotics after a patient is discharged from the hospital was a barrier to 
prescribing LAI antipsychotics. While several states have not permitted pharmacists to 
administer LAI antipsychotics, Kentuckians are fortunate that pharmacists are allowed to 
administer LAI antipsychotic injections. (Smart Retailing Rx, 2018). As the number of 
pharmacists allowed to administer non-vaccine injections increases across the country, patients 
will have improved access to LAI antipsychotics in the community setting. In addition to 
increased access to LAI antipsychotic injections in the community, many patients report higher 
satisfaction with receiving LAI antipsychotics from community pharmacists compared to 
alternative settings (Mooney et al., 2018). 
  The findings of this DNP project support that APPs knowledge regarding LAIs can 
improve after participating in an educational session, however if the project were to be 
conducted again it would be valuable to differentiate the scores of psychiatric mental health 
nurse practitioners and physician assistants. This would provide insight into which group of 
APPs benefit from educational sessions. It would also be beneficial to ask the participants what 
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they thought of the educational session so that future educational sessions could be tailored to 
APPs preferences.   
Implications 
 This DNP project demonstrates that implementing educational sessions can improve 
knowledge among advance practice providers. Utilizing existing resources, like “Long-Acting 
Injectable Antipsychotics: A Summary for Prescribers” by the Psychopharmacology Institute 
(Guzman, 2018), is only one example of how to provide current resources to improve the 
knowledge of advanced practice providers. A possible implication related to this DNP project 
would be the development of educational sessions specifically designed for advanced practice 
providers that are currently practicing. Many advanced practice providers hold an important role 
in the treatment of those with schizophrenia and education regarding LAI antipsychotics would 
likely improve the outcomes of those with schizophrenia.   
Limitations 
 A limitation of this DNP project included the small number of participants who met the 
inclusion criteria and agreed to participate. Only four out of the seven available advanced 
practice providers at ESH agreed to participate. Another limitation was the incomplete response 
by one of the participants when completing their pre-education assessment. This participant did 
not answer what they perceived as the largest barriers to prescribing LAI antipsychotics. 
Conclusion 
 Schizophrenia can be a difficult disorder to treat with as many as 74% of patients with 
schizophrenia becoming nonadherent with medications (Higashi et al., 2013). LAI antipsychotics 
are an effective alternative to traditional oral and older depot medications that have been shown 
to improve medication adherence and reduce relapse of patients’ psychotic symptoms (Green et 
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al., 2018). The importance of educating providers about LAI antipsychotics was supported by the 
results of this DNP project, but future studies should include later follow up to determine if 
improved knowledge can be sustained. Future studies should also evaluate if improved provider 
knowledge regarding LAI antipsychotics results in changes in provider prescribing behavior and 
improved patient outcomes.  
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Appendix A 
 
Pre-Education 
Long Acting Injectable (LAI) Antipsychotic Questionnaire  
 
 
1. LAI’s provide a better relationship between dose and blood levels because: 
a. LAI’s avoid first pass metabolism 
b. LAI’s provide higher and more frequent peak plasma levels 
c. LAIs require bridge therapy 
d. All LAI’s are administered q 2 weeks 
2. Plasma concentrations are: 
a. More stable with LAI’s compared to orally administered antipsychotics 
b. More stable with orally administered antipsychotics compared to LAI’s 
c. Equal regardless of antipsychotic administration route  
3. Side effects are: 
a. Less common with orally administered antipsychotics 
b. Less common with LAIs 
c. Equally common among LAI’s and orally administered antipsychotics  
4. Risk of re hospitalization is: 
a. Less common with LAI’s 
b. Less common with orally administered antipsychotics 
c. Equally common among LAI’s and orally administered antipsychotics 
5. Which LAI requires a 2-week bridge therapy? 
a. Risperdal Consta requires 2-week bridge with oral Risperidone 
b. Invega Sustenna requires 2-week bridge with oral Paliperidone 
c. Abilify Mantenna requires 2-week bridge therapy with oral Aripiprazole 
d. Invega Trinza requires 2-week bridge therapy with oral Paliperidone  
6. After the patient has a therapeutic level of the LAI, what would you recommend for the 
PO agent? 
a. Stop the oral medication 
b. Taper the oral medication 
c. Continue the oral medication along with the LAI 
7. Who should receive LAI’s? 
a. Only those who have not responded to 2 or more orally administered 
antipsychotics 
b. Those with recent onset psychosis 
c. Those with risk factors for medication noncompliance 
d. B & C 
8. What are potential advantages of LAI’s? (choose all that apply) 
a. LAI’s reduce the risks of accidental or deliberate overdose  
b. LAIs require slow dose titration 
c. LAI’s provide a mechanism for monitoring medication compliance 
d. A&C 
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9. What do you perceive as the largest barriers to prescribing LAI’s? 
 
 
 
 
 
 
 1. 
Strongly 
Disagree 
2. 
Disagree 
3. Neither 
Agree or 
Disagree 
4. 
Agree 
5. 
Strongly 
Agree 
10. Are you currently comfortable 
prescribing LAIs? 
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Appendix B 
 
Post-Education 
Long Acting Injectable (LAI) Antipsychotic Questionnaire  
 
 
10. LAI’s provide a better relationship between dose and blood levels because: 
a. LAI’s avoid first pass metabolism 
b. LAI’s provide higher and more frequent peak plasma levels 
c. LAIs require bridge therapy 
d. All LAI’s are administered q 2 weeks 
11. Plasma concentrations are: 
a. More stable with LAI’s compared to orally administered antipsychotics 
b. More stable with orally administered antipsychotics compared to LAI’s 
c. Equal regardless of antipsychotic administration route  
12. Side effects are: 
a. Less common with orally administered antipsychotics 
b. Less common with LAIs 
c. Equally common among LAI’s and orally administered antipsychotics  
13. Risk of re hospitalization is: 
a. Less common with LAI’s 
b. Less common with orally administered antipsychotics 
c. Equally common among LAI’s and orally administered antipsychotics 
14. Which LAI requires a 2-week bridge therapy? 
a. Risperdal Consta requires 2-week bridge with oral Risperidone 
b. Invega Sustenna requires 2-week bridge with oral Paliperidone 
c. Abilify Mantenna requires 2-week bridge therapy with oral Aripiprazole 
d. Invega Trinza requires 2-week bridge therapy with oral Paliperidone  
15. After the patient has a therapeutic level of the LAI, what would you recommend for the 
PO agent? 
a. Stop the oral medication 
b. Taper the oral medication 
c. Continue the oral medication along with the LAI 
16. Who should receive LAI’s? 
a. Only those who have not responded to 2 or more orally administered 
antipsychotics 
b. Those with recent onset psychosis 
c. Those with risk factors for medication noncompliance 
d. B & C 
17. What are potential advantages of LAI’s? (choose all that apply) 
a. LAI’s reduce the risks of accidental or deliberate overdose  
b. LAIs require slow dose titration 
c. LAI’s provide a mechanism for monitoring medication compliance 
d. A&C 
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18. What have you learned from the LAI education that might change your practice? 
 
 
 
 
 1. 
Strongly 
Disagree 
2. 
Disagree 
3. Neither 
Agree or 
Disagree 
4. 
Agree 
5. 
Strongly 
Agree 
10. After the education you received 
about LAIs are you more comfortable 
prescribing LAIs? 
     
11. After the education you received 
do you think you will prescribe LAIs 
more often? 
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Table 1. Pre and Post Assessment Results 
 Pre-education 
% correct 
Post-education 
%correct 
1. LAI’s provide a better 
relationship between 
dose and blood levels 
because: 
a. LAI’s avoid first 
pass metabolism 
b. LAI’s provide 
higher and more 
frequent peak 
plasma levels 
c. LAIs require 
bridge therapy 
d. All LAI’s are 
administered q 2 
weeks 
75% 100% 
2. Plasma concentrations 
are: 
a. More stable with 
LAI’s compared to 
orally 
administered 
antipsychotics 
b. More stable with 
orally 
administered 
antipsychotics 
compared to LAI’s 
c. Equal regardless 
of antipsychotic 
administration 
route  
75% 100% 
3. Side effects are: 
a. Less common with 
orally 
administered 
antipsychotics 
b. Less common 
with LAIs 
c. Equally common 
among LAI’s and 
75% 100% 
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orally 
administered 
antipsychotics  
4. Risk of re hospitalization 
is: 
a. Less common 
with LAI’s 
b. Less common with 
orally 
administered 
antipsychotics 
c. Equally common 
among LAI’s and 
orally 
administered 
antipsychotics 
100% 100% 
5. Which LAI requires a 2-
week bridge therapy? 
a. Risperdal Consta 
requires 2-week 
bridge with oral 
Risperidone 
b. Invega Sustenna 
requires 2-week 
bridge with oral 
Paliperidone 
c. Abilify Mantenna 
requires 2-week 
bridge therapy 
with oral 
Aripiprazole 
d. Invega Trinza 
requires 2-week 
bridge therapy 
with oral 
Paliperidone  
100% 75% 
6. After the patient has a 
therapeutic level of the 
LAI, what would you 
recommend for the PO 
agent? 
a. Stop the oral 
medication 
25% 75% 
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b. Taper the oral 
medication 
c. Continue the oral 
medication along 
with the LAI 
7. Who should receive 
LAI’s? 
a. Only those who 
have not 
responded to 2 or 
more orally 
administered 
antipsychotics 
b. Those with recent 
onset psychosis 
c. Those with risk 
factors for 
medication 
noncompliance 
d. B & C 
75% 100% 
8. What are potential 
advantages of LAI’s? 
a. LAI’s reduce the 
risks of accidental 
or deliberate 
overdose  
b. LAIs require slow 
dose titration 
c. LAI’s provide a 
mechanism for 
monitoring 
medication 
compliance 
d. A&C 
100% 100% 
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